{"url":"https://newsforagent.com/news/2026-11-21/kyverna-therapeutics-kahn-swick-foti-investigation","markdown_url":"https://newsforagent.com/news/2026-11-21/kyverna-therapeutics-kahn-swick-foti-investigation.md","title":"Kyverna Therapeutics Faces Kahn Swick & Foti Investigation","headline":"Kahn Swick & Foti Investigates Kyverna Therapeutics Over IPO Disclosures","description":"Kahn Swick & Foti has opened an investigation into Kyverna Therapeutics, examining whether officers breached duties.","section":"Legal & Disputes","published_at":"2026-11-21T03:52:55+00:00","modified_at":"2026-11-21T03:52:55+00:00","author":"News Desk","key_takeaways":["Kahn Swick & Foti has commenced an investigation into Kyverna Therapeutics and whether its officers or directors breached fiduciary duties.","A securities lawsuit alleges Kyverna's February 8, 2024 IPO registration statement and prospectus misstated or omitted material facts about KYV-101 trial results.","Kyverna initiated a rolling Biologics License Application submission to the FDA for mivocabtagene autoleucel in stiff person syndrome in May 2026."],"companies":[{"name":"Kyverna Therapeutics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00004ng/kyverna-therapeutics","website":"http://kyvernatx.com"},{"name":"Kahn Swick & Foti","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0002uis/kahn-swick-foti","website":"http://www.ksfcounsel.com"}],"source":{"publisher":"PR Newswire","title":"Kyverna Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX","url":"https://www.prnewswire.com/news-releases/kyverna-therapeutics-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc---kytx-302947399.html"},"other_sources":[],"tags":["Legal & Disputes","Kyverna Therapeutics","Kahn Swick & Foti"],"body_markdown":"[Kahn Swick & Foti](https://akta.pro/company-profiles/0002uis/kahn-swick-foti), LLC has commenced an investigation into [Kyverna Therapeutics](https://akta.pro/company-profiles/00004ng/kyverna-therapeutics), Inc., examining whether the company's officers or directors breached fiduciary duties to shareholders or otherwise violated state or federal laws, according to a [PR Newswire](https://www.prnewswire.com/news-releases/kyverna-therapeutics-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc---kytx-302947399.html) announcement. The firm said the inquiry follows a securities lawsuit concerning Kyverna's February 8, 2024 initial public offering.\n\n## What the Kyverna Securities Suit Alleges\n\nThe lawsuit claims the registration statement and prospectus Kyverna used for its IPO misstated or omitted material facts about results from the company's ongoing clinical evaluation of KYV-101, its lead product candidate. According to the suit, Kyverna touted patient \"improvement\" in certain indicators while failing to disclose adverse data from one of its clinical trials, even though that data was known to the company at the time of the IPO. The lawsuit alleges investors purchased Kyverna shares at artificially inflated prices and suffered damages when the true details entered the market.\n\nKahn Swick & Foti's partners include Charles C. Foti, Jr., a former Attorney General of Louisiana. The firm states that it was ranked by SCAS among the top 10 firms nationally based upon total settlement value this past year. The firm's investigation is focused on whether Kyverna's officers and/or directors breached their fiduciary duties to shareholders.\n\n## Kyverna's Clinical and Funding Record\n\nKyverna is a clinical-stage biopharmaceutical company developing anti-CD19 CAR T-cell therapies for B-cell-driven autoimmune diseases, with miv-cel (KYV-101) in registrational trials for stiff person syndrome, myasthenia gravis, lupus nephritis and multiple sclerosis, according to akta.pro [company records](https://akta.pro/company-data). The same records show Kyverna initiated a rolling Biologics License Application submission to the FDA for mivocabtagene autoleucel in stiff person syndrome in May 2026, described as the first BLA for a CAR-T therapy in an autoimmune indication. Kyverna closed a $100 million follow-on public equity offering in December 2025 to support registrational development and commercial-scale manufacturing capacity, the records show.\n\n## Earlier Kyverna Governance Inquiries\n\nHalper Sadeh LLC said in October 2026 that it was investigating whether Kyverna Therapeutics officers and directors breached fiduciary duties to shareholders, PR Newswire reported. In September 2026, Kyverna presented its miv-cel pipeline at the Wells Fargo Healthcare Conference, highlighting a pivotal trial in stiff person syndrome showing reversal of disability and drug-free remission, Investing.com reported. Kyverna reported a net loss of $38.3 million and $199.4 million in cash in its second quarter 2026 financial results, GlobeNewswire reported.\n\n## Kyverna's FDA Submission Timeline\n\nKyverna plans to submit a biologics license application to the FDA by year-end for miv-cel in stiff person syndrome, BioSpace reported in July 2026. The company has said the submission would make miv-cel the first cell therapy approved for an autoimmune disease.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}